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Abstract
We consider modelling and inference as well as sample size estimation and
reestimation for clinical trials with longitudinal count data as outcomes. Our approach
is general but is rooted in design and analysis of multiple sclerosis trials where
lesion counts obtained by magnetic resonance imaging are important endpoints.
We adopt a binomial thinning model that allows for correlated counts with marginal
Poisson or negative binomial distributions. Methods for sample size planning and
blinded sample size reestimation for randomized controlled clinical trials with such
outcomes are developed. The models and approaches are applicable to data with
incomplete observations. A simulation study is conducted to assess the effectiveness
of sample size estimation and blinded sample size reestimation methods. Sample
sizes attained through these procedures are shown to maintain the desired study
power without inflating the type I error. Data from a recent trial in patients with
secondary progressive multiple sclerosis illustrate the modelling approach.
Keywords
adaptive design, lesion counts, sample size reestimation, negative binomial, discrete
autoregressive process, time dependent
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1 Introduction
Many biological experiments and clinical trials use count data as primary outcomes, for
example the number of events within a certain time frame. Our particular interest is in
the context of multiple sclerosis (MS) clinical trials, where the number of brain lesions
assessed at regular intervals by magnetic resonance imaging (MRI) form an important
measure of disease severity.1 The response of interest is thus longitudinal count data,
and because counts tend to be low, the highly discrete nature of the response needs to be
taken into account properly, in design and analysis. We consider both in this article.
A variety of analysis methods are available for longitudinal count data.2 Examples
include early consideration of integer time series as Markov chains,3–5 later alternative
transition or other parametric models,6–9 and general classes of model-free estimating
equations10,11 or random effect and latent process approaches.12–15 Given that count data
are commonly assumed to follow possibly overdispersed Poisson or negative binomial
distributions, and that a fully specified model is needed for sample size estimation, our
preference is for a parametric approach which accounts for within-person dependence
but maintains negative binomial marginal distributions. While this can be true for certain
frailty models12,14 a binomial thinning construction formally introduced by Steutel and
van Harn16 can lead to an intuitive mechanistic interpretation for lesion count data,
as we will explain later. Hence the approach we take is an adaptation of the binomial
thinning developments of McKenzie,17 and Al-Osh and Alzaid.18 This will be described
in Section 3.
Turning to design, an important step in the planning of clinical trials is the
determination of an appropriate sample size for primary, secondary and sometimes
also key outcomes. However, when calculating the sample size required to achieve
a certain power, assumptions on the distribution of the outcome have to be made.
Such assumptions are of course subject to uncertainty, which might be amplified if the
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proposed trial has different characteristics from the historical trials used to inform sample
size calculation, such as different eligibility criteria perhaps, or variations in length of
follow up. Adaptive study designs using an internal pilot study (IPS) to reestimate the
sample size, based on the distribution of outcomes observed in interim data, can reduce
uncertainty19 and have been encouraged by regulatory authorities.20,21 In comparison
to final analyses, analyses on interim data are often more challenging. Firstly, unblinded
analyses at interim bear the risk of introducing bias to the study. To avoid these unwanted
influences on the study outcome, an unblinding of the interim data is not recommended
and should be avoided whenever possible.22 Secondly, at interim many patients recruited
into the study might only have provided incomplete follow up. Therefore, any sample
size reestimation procedure should be applicable to blinded data and allow data with
incomplete follow up. In this paper, we focus on developing procedures for sample
size estimation and blinded sample size reestimation (BSSR) in randomized controlled
two-arm trials, by using the proposed modelling approach to address the challenge of
incomplete follow up times. Statistical inference is then performed on the ratio of group
specific rates.
The paper is organised as follows. In Section 2 we give some background on MS
studies and lesion count outcomes and we describe two trials which we use to calibrate
our approach. Section 3 continues with a description of the proposed binomial thinning
model as well as a formal derivation of a Wald-type test statistic for inference on
the ratio of experimental and control group rates. In Section 4 we derive sample
size estimation and blinded sample size reestimation procedures and in Section 5 we
demonstrate these procedures in retrospect on a recent MS trial. Simulation results to
investigate the accuracy of the proposed procedures are described in Section 6 and the
paper is concluded in Section 7 with discussion of possibilities for further extending the
modelling approach.
2 Lesion counts and MS-trials
Lesion counts from MRI play an essential role in the diagnosis of MS.23 They are
used as supportive secondary outcomes in phase III trials but are established as primary
outcome measures in phase II trials, which tend to be shorter and smaller in terms
of number of patients enrolled, and rely on short-term indicators of disease activity.24
Lesion counts seem to fulfill the requirements of such a sensitive indicator.25–27 In MRI,
different techniques have been developed to visualize lesions. Two classic measures are
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T1-hypointense lesions, also referred to as ‘black holes’ and T2-hyperintense lesions,
also referred to as ‘white spots’. These lesion types are inter-related yet different. T1-
hypointense lesions appear as dark areas on an image and may arise from severe chronic
demyelination, inflammation, permanent axonal damage and gliosis through multiple
sclerosis. They may also represent areas of edema or swelling, and can be temporary
and disappear in subsequent scans. T2-hyperintense lesions in contrast can show the
total number of lesions as they are a marker of past injury, which only rarely disappear
completely.28 Both imaging endpoints have been considered as endpoints in numerous
MS studies.29–34 T2 lesions have been shown to be a reasonable surrogate for the number
of relapses, both for relapsing-remitting MS (RRMS) and secondary progressive MS
(SPMS).35,36
There are two quite different modelling strategies for lesion count data in MS. One
relies on assuming the marginal distributions of lesion counts at observation times to be
negative binomial,37 whereas the second relies on an assumption that the sum of lesion
counts over a certain time span is negative binomial.38 Both modelling possibilities seem
adequate when investigating real data, but when the observations are dependent, in theory
only one can be true, since the sum of dependent negative binomial distributed variables
generally does not follow a negative binomial distribution. The second, accumulation,
approach has advantages in leading to simpler analyses, but the first is more flexible in
modelling and in handling data with incomplete follow up. In the following, we will thus
use a model which allows for marginal distributions of lesion counts to be from a negative
binomial distribution.
For illustration and motivation of the techniques to come, we will consider two very
different MS studies in which counts of T2 lesions have been used as endpoints. The
first is a study conducted by Tubridy et al.,39 which investigated whether the T2 outcome
distribution depends upon the type of MS. It listed newly active lesions at monthly MRI
scans for 31 RRMS patients and 26 SPMS patients from natural history studies or placebo
arms of therapeutical trials, with six months follow up per patient. The second example
we consider is a randomized controlled trial by Chataway et al.29 The study aimed
at demonstrating an effect of high-dose simvastatin on brain atrophy and disability in
SPMS. For this purpose, 140 patients were randomly assigned (1:1) to receive either 80
mg of simvastatin or placebo. The trial was planned to go over 4 years with a recruitment
phase of 2 years. Each of the 140 patients was followed up for 25 months. The primary
outcome was the annualised rate of whole-brain atrophy measured from serial volumetric
MRI. However, a secondary outcome, to be considered here, was new and enlarging T2
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lesions, monitored at approximately annual MRI scans (baseline, month 12 and month
25).
3 Proposed model and Wald-type test
3.1 Modelling autoregressive negative binomial observations
We propose a statistical model which relies on a binomial thinning operation, developed
by Steutel and van Harn,16 to maintain integer based values within a time series. Suppose
we observe nC patients in the control group and nE patients in the experiment group over
a total of T time points. We will denote the observed counts of patient j of group i at
time point t by X(t)ij where i = E,C, j = 1, . . . , ni and t = 1, . . . , T . To model these
observations in such a way, that they are dependent over time points and marginally
negative binomial distributed, we reparametrise a negative binomial integrated value
autoregressive process of first order (NB-INAR(1)), first proposed in McKenzie.17 In the
following, we specify the reparametrised model explicitly and show its most important
properties.
Observations from the NB-INAR(1) model are given by
X
(t)
ij =
X
(t−1)
ij∑
k=1
B
(t)
ijk(U
(t)
ij ) +W
(t)
ij for t = 2, . . . , T, j = 1, . . . , ni, i = E,C, (1)
where the random variables observed at the first time point X(1)ij are defined as
negative binomial random variables with mean λi and shape parameter η, i.e. X
(1)
ij
i.i.d.∼
NB(λi, η). The desired marginal negative binomial property and correlation between
observations X(t)ij are attained through mixture distributions using the random variables
B
(t)
ijk(p), Bernoulli distributed random variables with parameter p, i.e. B
(t)
ijk(p)
i.i.d.∼
Bernoulli(p), the random variables U (t)ij , beta distributed random variables with
parameters aη and (1− a)η, i.e. U (t)ij i.i.d.∼ Beta (aη, (1− a)η), and an independent
random variable W (t)ij
i.i.d.∼ NB ((1− a)λi, (1− a)η), which is added to the random
sum. It can be shown17 that combining the random variables in this way the observations
marginally follow a negative binomial distribution, i.e. X(t)ij ∼ NB(λi, η) for j =
1, . . . , ni, i = E,C and t = 1, . . . , T , and the covariance between observations at time
points t and t+ k is Cov(X(t)ij , X
(t+k)
ij ) = a
k · (λi + λ2i /η). For completeness we
provide details and proofs in Appendices A and B.
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The model is thus parametrised through λE , λC ∈ (0,∞), a ∈ [0, 1] and η ∈ (0,∞).
The lesion rates of the experiment group and control group are given through λE and
λC respectively. The parameter a is a correlation parameter, which influences the degree
to which two time points are dependent. At a = 0 observations are independent, while
at a = 1 observations are fully dependent over time. The NB-INAR(1) model is further
parametrised by a shape parameter η, which influences the amount of overdispersion
observed in the marginal observations. Lower values of η indicate a higher degree
of overdispersion. The assumption of a common shape parameter is frequently made,
for example in standard statistical software (e.g. SAS, R). However, we point out that
generally it would also be possible to define the model with group-specific nuisance
parameters.
In contrast to alternative models which also allow for dependent count data with
negative binomial marginals, e.g. serially correlated gamma frailty models,12,14 the
model does not include subject-specific covariates or time trends. However, it has the
significant advantage that the full likelihood can be computed, marginal observations can
be fully dependent, and closed-form method-of-moment estimators are available. It also
has a mechanistic interpretation which would be appropriate for T1 counts in MS trials, as
follows. A random proportion of lesions observed at time point t continues to time point
t+ 1, symbolized through the random sum in (1), together with independently occurring
new lesions given through W (t)ij . For T2 lesions this mechanistic interpretation does not
hold, as T2 lesions rarely disappear. Nevertheless, having correlated counts and marginal
negative binomial distribution are appropriate properties for modeling T2 lesion counts.
3.2 Fitting the proposed model to data from the example studies
To give an indication of how data from the NB-INAR(1) model compares to real data
from our examples, we considered MRI lesion counts from the previously mentioned
MS studies.29,39 We compare the calculated mean and shape parameter implied by
the model with observed marginal means and shape parameters attained by negative
binomial regression. Pointwise 95% confidence intervals for marginal estimates are also
provided. Further, the mean correlation of two consecutive time points is compared to the
correlation imposed by the NB-INAR(1) model. Figure 1 shows the observed data and
compares the fitted model to observed mean and shape parameter.
The NB-INAR(1) model appears to capture the marginal mean and shape parameter
well for the data from Tubridy et al.39 and Chataway et al.29 alike. Model means are
very close to the empirically observed means. Furthermore, the observed means do not
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Figure 1. T2 lesion counts attained from Tubridy et al. 39 (first and second from left) and
Chataway et al. 29 (third and fourth from left). The data from Tubridy et al. 39 contains new T2
lesion counts from placebo groups or patients natural history, separated according to SPMS
and RRMS patients. The data was gathered over 6 months with monthly MRI scans. Data
from Chataway et al. 29 contains new and enhancing T2 lesion counts from yearly MRI scans.
In this case, new and enhancing lesion counts were measured 12 and 25 months after trial
start.
seem to show a trend, so the assumption of constant rates seems plausible. The shape
parameter observed in the data from Tubridy et al.39 is not described as well, as it
is rather heterogeneous across time points, while the NB-INAR(1) model assumes a
constant shape parameter. Empirical pairwise correlations and model correlation are also
different for the data from Tubridy et al.39 This may partially be due to the relatively low
sample size available. Both correlation and shape parameter are captured better for the
data from Chataway et al.29
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3.3 Derivation of a Wald-type test
We consider the NB-INAR(1) model introduced in Section 3.1, and denote the ratio of
group rates by θ = λE/λC . In this section we use moment estimators to develop a closed-
form Wald-type statistic for testing the null hypothesis H0 : θ = 1 against the one-sided
alternative H1 : θ < 1. The closed-form is especially useful when deriving a sample size
formula, and would not have been attainable through a maximum likelihood approach
using the observed Fisher information. The methods presented can be generalised to
testing two sided hypotheses as well as absolute differences of the treatment rates.
Moment estimators for lesion rates λi, i = E,C are given by
λ̂i =
1
T · ni
ni∑
j=1
T∑
t=1
X
(t)
ij for i = E,C.
By the central limit theorem we have λ̂i
approx∼ N(λi, 1/ni · (λi + λ2i /η)ρ) where
ρ =
1
T 2
T∑
t=1
T∑
s=1
a|t−s| (2)
is referred to as the dependency parameter. Applying the delta method yields
log(λ̂i)
approx∼ N(log(λi), (λ−1i + η−1)ρ/ni). The asymptotic distribution of λ̂i can be
used to attain a pivotal quantity W
W =
log(λ̂E/λ̂C)√
ρ ·
(
1
nE
( 1λE +
1
η ) +
1
nC
( 1λC +
1
η )
) approx∼ N(µ, 1),
where the mean µ is given by
µ =
log(λE/λC)√
ρ ·
(
1
nE
( 1λE +
1
η ) +
1
nC
( 1λC +
1
η )
) .
To attain a Wald-type test statistic Z, for testing the stated null hypothesis H0 : θ = 1,
we further require estimators for the dependency parameter ρ and shape parameter η.
Using the properties of the model, we can estimate ρ through the mean of all entries of
the empirical correlation matrix. Since the means of the experiment and control group
may be unequal, the correlation matrix is pooled accordingly. The resulting estimator ρ̂
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is
ρ̂ =
1
(n1 + n2 − 2)T 2
∑
i=E,C
T∑
t=1
T∑
s=1
ni∑
k=1
(
X
(t)
ik −X
(t)
i·
)(
X
(s)
ik −X
(s)
i·
)
√
ni∑
k=1
(
X
(t)
ik −X
(t)
i·
)2 ni∑
k=1
(
X
(s)
ik −X
(s)
i·
)2 .
Rather than estimating λi and η separately and plugging the estimators into the
denominator, the complete expression 1/λi + 1/η is estimated by
1̂
λi
+
1
η
=
1
(ni − 1)T λ̂i
2
T∑
t=1
ni∑
k=1
(
X
(t)
ik −X(t)i·
)2
.
Estimating the complete term, rather than plugging in separate estimates for λi and η,
avoids the problem of negative shape parameter estimates when using moment estimators
on underdispersed data. The case of no dispersion or underdispersion, however, is not
typical for lesion counts of MS trials.37
By replacing all unknown parameters of the pivotal quantity W with their
corresponding estimators, we attain a Wald-type test statistic which, by means of
Slutsky’s theorem, can be shown to be asymptotically normal distributed. The resulting
statistic Z, for testing the null hypothesis H0 : θ = 1, is
Z =
log(λ̂E/λ̂C)√
ρ̂ ·
(
1
nE
( 1̂λE +
1
η ) +
1
nC
( 1̂λC +
1
η )
) approx∼ N(0, 1). (3)
3.4 Numerical example
To demonstrate the use of the derived Wald-Test we consider the previously mentioned
example data from Chataway et al.29 Of the originally planned 140 patients, for 10
patients only baseline scans were provided. These patients were therefore discarded from
the analyses presented in Chataway et al.29 A further 8 patients had missing data on the
12 month MRI scan and 6 patients had no data on the 25 month MRI scan. We will
discard the patients who did not have data on the 12 month MRI scan but consider the
case of including the 6 patients with incomplete follow up. Therefore we consider two
cases for inference.
1. Complete follow up only, with 55 patients in the placebo group and 61 patients in
the control group.
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2. Incomplete follow up, with 60 patients in the placebo group and 62 patients in the
treatment group.
To assess for rate differences between control and treatment group, Chataway et al.
performed a quasi-Poisson regression on the cumulative number of new lesions with
adjustment for patient-specific characteristics. As the NB-INAR(1) model does not allow
for covariates, for comparison purposes we repeat the quasi-Poisson regression40 on the
cumulative lesions counts without covariates, but including the number of scans as an
offset variable in the case of incomplete follow up. The results are compared in Table 1
with results attained through the derived Wald-test and also with a test based on negative
binomial regression41 on the cumulative number of new lesions.
Table 1. Comparison of inference methods for testing the effect size log rate ratio (logRR)
with standard error (SE) and rate ratio (RR) with 95% confidence interval (CI). Analysis are
performed separately on complete and incomplete follow up. All p-values are one sided.
Follow up Method logRR (SE) RR (95% CI) Z p-value
C
om
pl
et
e Quasi-Poisson -0.39 (0.26) 0.68 (0.41-1.11) -1.53 0.0639
Negative Binomial -0.39 (0.26) 0.68 (0.41-1.12) -1.51 0.066
NB-INAR(1) Wald-Test -0.39 (0.26) 0.68 (0.41-1.12) -1.51 0.065
In
co
m
pl
et
e
Quasi-Poisson -0.45 (0.26) 0.64 (0.38-1.07) -1.71 0.0446
Negative Binomial -0.48 (0.25) 0.62 (0.37-1.01) -1.91 0.0283
NB-INAR(1) Wald-Test -0.45 (0.25) 0.64 (0.39-1.05) -1.78 0.0378
Table 1 displays the (log) rate ratio of mean relapse rates in the treatment group and the
control group with standard errors for the log rate ratio, 95% confidence intervals for the
rate ratios, Z-statistics and p-values (assuming normal approximation of the Z-statistic).
Overall, the results appear to be similar across the methods. Especially for data with
complete follow up, all three methods give almost equal results. The main difference
occurs when incomplete follow up is considered for inference. The negative binomial
regression with offset variable estimates a slightly larger effect size than Quasi-Poisson
with offset and the NB-INAR(1) Wald-Test, resulting in a lower p-value.
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4 Sample size formula and blinded sample size reestimation
4.1 Sample size: pre-trial calculation
Next we consider the derivation of a sample size formula given test size α, target power
1− β and specified clinically important effect size θ∗. Having the test statistic Z (3)
in closed form means this is a relatively straightforward calculation. Given the null
hypothesis is true,Z approximately follows a standard normal distribution and we simply
need to solve Φ(zα − µ∗) = 1− β, where Φ(.) is the N(0,1) distribution function, zα is
the appropriate critical value and µ∗ is the mean of Z at θ∗. Letting k = nE/nC this
gives
nC =
(zβ + zα)
2 · ρ
log(θ∗)2
(
(1 + kθ∗)2
(1 + k)kθ∗λ
+
1
η
(
1 +
1
k
))
, (4)
where λ = (kλE + λC)/(k + 1) is the overall lesion rate. In the special case of
independent observations, i.e. a = 0, the formula simplifies with ρ = 1/T . Therefore,
adding an observation time point to the experiment is equivalent to recruiting further
nC + nE patients. In the case of fully dependent observations, i.e. a = 1, adding further
time points to the experiment does not improve the power and therefore does not
influence the sample size. This is reflected through ρ = 1 and the formula reduces to
the simpler case of a two group comparison with one time point, considered in Friede
and Schmidli.42
To assess the accuracy of the proposed sample size formula, we ran a small simulation
study to compare actual power with target for a range of values of the nuisance parameters
λ, a and η. We took a significance level of α = 0.025, 80% power, number of time points
T = 7, and sample size allocation parameter k = 1. We assumed the true effect size
matched the specified clinically relevant effect size and took θ∗ = θ = 0.8. The nuisance
parameter ρ was implied by a and T through (2). All settings were simulated a total of
100, 000 times. The calculated sample sizes and achieved power are displayed in Table 2.
In all cases the achieved power is within simulation noise (standard deviation 0.13%) of
the target. Sample sizes tend to be smaller when counts are higher or less variable, larger
when there is strong within-patient dependence.
While the relevant effect θ∗ is chosen based on clinical considerations, the overall
lesion rate λ, the correlation parameter a, as well as the shape parameter η are unknown
nuisance parameters and have to be estimated from previous trials or guessed. The need
for precise nuisance parameter estimates is even stronger in situations where the sample
size is sensitive to small changes of these. To study the influence of changes in nuisance
Prepared using sagej.cls
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Table 2. Sample size calculations and corresponding simulated power for selected settings.
λ a (ρ) η Calculated Sample Size (nC = nE) Simulated Power
1.0 0.3 (0.24) 0.8 171 79.8 %
1.0 0.3 (0.24) 1.6 124 79.9 %
1.0 0.6 (0.42) 0.8 301 80.1 %
1.0 0.6 (0.42) 1.6 218 80.0 %
2.5 0.3 (0.24) 0.8 125 79.7 %
2.5 0.3 (0.24) 1.6 78 80.2 %
2.5 0.6 (0.42) 0.8 221 80.2 %
2.5 0.6 (0.42) 1.6 137 80.1 %
parameters on the sample size formula, we interpret nC as a function of the nuisance
parameters and consider the derivatives with respect to the nuisance parameters. The
derivatives of nC(λ, η, a) with respect to the overall rate λ and shape parameter η are
∂nC(λ, η, a)
∂λ
= − 1
λ
2 ·
(zβ + zα)
2ρ(1 + kθ∗)2
log(θ∗)2(1 + k)kθ∗
and
∂nC(λ, η, a)
∂η
= − 1
η2
· (zβ + zα)
2ρ(1 + 1k )
log(θ∗)2
.
These reveal, that the sample size formula is especially sensitive to changes of the overall
rate λ and shape parameter η, when these are near zero. The higher the parameter values
are, the lower the impact of small changes to the parameters on the calculate sample size.
The derivative of nC(λ, η, a) with respect to the correlation coefficient a is
∂nC(λ, η, a)
∂a
=
(T − 1)aT+1 − (T + 1)aT + a(T + 1)− T + 1
(a− 1)3 ·
(zβ + zα)
2
log(θ∗)2
(
(1 + kθ∗)2
(1 + k)kθ∗λ
+
1
η
(
1 +
1
k
))
.
Analyzing the influence of the correlation coefficient is not as straightforward. To gain
some insights on the influence of the correlation coefficient on the sample size formula,
we consider the two cases of independent (a = 0) observations, which results in
lim
a→0
∂nC(λ, η, a)
∂a
= (T − 1) · (zβ + zα)
2
log(θ∗)2
(
(1 + kθ∗)2
(1 + k)kθ∗λ
+
1
η
(
1 +
1
k
))
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and fully dependent (a = 1) observations resulting in
lim
a→1
∂nC(λ, η, a)
∂a
=
1
6
T (T 2 − 1) · (zβ + zα)
2
log(θ∗)2
(
(1 + kθ∗)2
(1 + k)kθ∗λ
+
1
η
(
1 +
1
k
))
.
From the two special cases, we conclude that the sample size is especially sensitive to
changes of the correlation parameter when it is near 1 and the number of time points
is high. It is in these situations, in which the sample size is sensitive to the nuisance
parameters, that a reestimation of the nuisance parameters can be highly beneficial for
attaining a reliable sample size estimate.
4.2 Sample size: blinded reestimation
For blinded sample size reestimation within the NB-INAR(1) model, we require
estimators for the nuisance parameters λ, a and η applicable on blinded data. Although
moment estimators can be derived, we observed that maximum likelihood estimators
are more efficient and imply a smaller standard deviation of the resulting sample size
estimate. This observation is supported by general asymptotic theory and by other
literature in the context of blinded parameter estimation.43
Let x(t)j denote the observations from individual j = 1, . . . , nE + nC at time point
t = 1, . . . , T . Then the likelihood function for blinded estimation is
L
(
x
(1)
1 , . . . , x
(T )
nE+nC
)
=
nE+nC∏
j=1
(
f
X
(1)
j
(x
(1)
j ) ·
T−1∏
t=1
f
X
(t+1)
j |X(t)j
(x
(t+1)
j )
)
, (5)
where f
X
(1)
j
(x
(1)
j ) is the marginal probability function of the first count and the
subsequent conditional probabilities f
X
(t+1)
j |X(t)j
(x
(t+1)
j ) exploit the Markov structure of
the model (1). Letting PNB(x, µ, φ) denote the probability function of a negative binomial
random variable with mean µ and shape parameter φ, the first observation has a mixture
distribution
f
X
(1)
j
(x
(1)
j ) =
1
1 + k
·
[
k · PNB
(
x
(1)
j ,
λ(1 + k)
k + 1/θ
, η
)
+ PNB
(
x
(1)
j ,
λ(1 + k)
1 + kθ
, η
)]
.
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Later observations have conditional probability functions
f
X
(t+1)
j |X(t)j
(x
(t+1)
j ) =
1
1 + k
min(x
(t+1)
j ,x
(t)
j )∑
y=0
(
x
(t)
j
y
)
B(aη + y, (1− a)η + x(t)j − y)
B(aη, (1− a)η) ·[
kPNB
(
x
(t+1)
j − y,
λ(1 + k)
k + 1/θ
, (1− a)η
)
+ PNB
(
x
(t+1)
j − y,
λ(1 + k)
1 + kθ
, (1− a)η
)]
where B(x, y) = Γ(x)Γ(y)/Γ(x, y) with Γ(x) =
∞∫
0
tx−1e−tdt. Numerically maximis-
ing the likelihood constructed from (5) and the above expressions leads to estimates of λ,
η and a which can be substituted into the sample size formula (4) to attain a blinded
sample size reestimate. Unlike other approaches which estimate nuisance parameters
from blinded data for blinded sample size reestimation, e.g. Friede and Schmidli,42
observations are not assumed to be from a common negative binomial distribution, but
from a mixture distribution between two negative binomial distributions with unequal
means.
4.3 Extension to incomplete observations
When performing blinded sample size reestimation within a running trial, the experiment
supervisor will almost always be confronted with incomplete observations at an interim
analysis. This is frequently due to the underlying recruitment plans for such clinical trials.
Figure 2 shows a possible recruitment scheme and its consequences for a sample size
review.
If a sample size review is to be performed at 12 months, we see that numerous patients
still have incomplete follow up. One advantage the proposed method offers over using a
summary statistic as in Friede and Schmidli,42 is that such incomplete observations can
be considered for the blinded estimation of nuisance parameters. Data on these patients
can significantly improve the estimation of nuisance parameters and should therefore
not be ignored. Fortunately for our model incomplete observations can be incorporated
within the likelihood function, in a blinded fashion, simply by allowing subject-specific
final timepoints Tj for j = 1, . . . , nE + nC opposed to a fixed follow up time T as in
(5).
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Figure 2. Possible recruitment scheme for a 24-month clinical trial, leading to incomplete
observations at sample size review. Each line corresponds to one patient and the length of
the line to the time in which the patient is examined. Thus, each patient is examined for a total
of 7 months.
5 Example
To illustrate the initial sample size estimation and benefits of reestimation procedures,
we retrospectively consider the previously mentioned simvastatin trial.29
5.1 Sample size: pre-trial calculation
To use the sample size formula (4) we need the design values and some knowledge of the
nuisance parameters. In this example, design values are the number of time points T = 2,
desired power 1− β = 0.8, type I error α = 0.025 and sample size allocation factor
k = 1. Further, the relevant effect which we would like to detect is θ∗ = 0.6. To estimate
the nuisance parameters we need to find comparable studies from which to extract
information. The simvastatin trial was planned around 2005, so the sample size estimates
relied on publications before this year. However, especially in MRI studies before 2005,
many different methods of counting new lesions can be found. For example, some authors
count only new lesions44 while others count new and enhancing lesions45 or new and
enlarging lesions.46 Furthermore, there are different methods of adjusting lesions for
baseline and further covariates, rendering comparisons between studies revolving around
SPMS difficult if not impossible. For our illustration, estimates were based on Cohen et
al.46 This study included 385 SPMS patients in a 2-year placebo-controlled trial, with,
as a secondary outcome, newly active or enlarging lesions, counted on a yearly basis.
After some calculation from the summary information provided, the annual new active
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lesion rate was estimated to be in the region of λC = 1. Then, assuming a treatment effect
of θ = 0.6 and k = 1, the estimated overall rate is λ = 0.8. Further, a shape parameter
estimate of η = 0.58 seems appropriate. Unfortunately the correlation parameter cannot
be estimated from the data provided by Cohen et al.:46 we will simply use an estimate of
a = 0.4 (with T = 2, this corresponds to ρ = 0.7). Applying the sample size formula (4)
then leads to nC = nE = 129 for our hypothetical design. Recall that the real design29
had nC = nE = 70.
5.2 Sample size: blinded reestimation
To select an appropriate time point for an interim analysis, we require some knowledge
of the underlying recruitment scheme. Figure 3 shows the recruitment scheme observed
within the trial.
Figure 3. Recruitment scheme of the simvastatin trial. 29 The first MRI corresponds to the
baseline count. The second MRI was conducted 12 months and the third MRI 25 months after
baseline. A sample size reassessment 30 months after the start of the study would be
possible by using the complete observations (green) and the incomplete observations (red).
From the recruitment scheme it seems that the earliest sensible time point for an interim
analysis is after about 2.5 years into the study. At earlier time points there would be
no patients with two consecutive observations after baseline, making it impossible to
estimate the correlation parameter. Unfortunately, in this study, recruitment would have
Prepared using sagej.cls
Asendorf et al. 17
already ended when performing the interim analysis. It would have been more desirable
to perform a sample size reassessment after about 1.5 years, but doing so would have
required MRI scans every 6 months. From this example we note that planning of an
interim analysis for sample size reassessment requires taking into account the recruitment
speed of patients as well as the frequency at which MRI scans are taken.
Assuming a sample size reassessment at 2.5 years leads to reestimated values of
nC = nE = 97. The nuisance parameters at 2.5 years were estimated to be λ = 2.70,
η = 0.56 and a = 0.42. Thus, the planned sample size of 129 patients in each group is
too high and the annual new active lesion rate and shape parameter were both initially
underestimated. The difference between the marginal distribution assumed prior to the
study and the marginal distribution estimated at the interim analysis is most noticeable in
the probability of observing 0 new lesion counts. For the initially assumed distribution,
the probability of observing 0 lesion counts is approximately 56%, much higher than the
observed distribution at the interim analysis. At interim, the probability of observing 0
new lesions in a patient was approximately 34%.
6 Operating characteristics of the blinded sample size
reestimation
We conducted a two-part simulation study to assess the effectiveness of the proposed
BSSR procedure. In the first part, the fixed design is compared to the BSSR procedure in
terms of significance level and power. In the second part, benefits of including patients
with incomplete follow up for the sample size reestimation are examined. Throughout
we took T = 7, one-sided test size α = 0.025, target power 1− β = 0.8, and allocation
factor k = 1. For each resulting setting 10, 000 simulation runs were conducted.
6.1 Significance level simulation of BSSR procedure vs. fixed
sample size estimation
In a first simulation, we compare test sizes when 1) the a priori sample size was
maintained, and 2) when sample size was adjusted following the BSSR procedure after
half the (initial) target number of patients have been recruited. We assume full follow
up for these patients: incomplete data will be considered later. The procedure can be
summarized in four steps.
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1. The initial sample size is calculated by plugging in assumed nuisance parameters
λ = 2, a = 0.5 and η = 1 and relevant effect size of θ∗ = 0.8 into the sample size
formula (4). With these parameters, the estimated sample size of the control and
treatment group are both given by nest = 165.
2. Next nest/2 observations are simulated for the control and treatment group
respectively, corresponding to the first half of patients. The data is simulated under
the null of no treatment effect (θ = 1) and various selections of true nuisance
parameters. We took an array of values for the true nuisance parameters: a =
0.3, ..., 0.7 in steps of 0.05, η = 0.5, ..., 1.5 in steps of 0.1 and λ = 1.5, ..., 2.5
in steps of 0.1. Thus, in total 1089 different settings were considered. Because all
a priori fixed sample sizes were calculated by using the same assumed nuisance
parameters, these are misspecified in all but one of the settings.
3. A blinded sample size reestimation is performed on the simulated observations, to
attain a reestimated sample size nreest.
4. Finally, the attained significance level of the fixed design based on the initial
nest = 165 observations in each group is compared to the significance level of
the BSSR design based on nreest observations in each group. The number of
observations in the BSSR design is allowed to be higher or smaller than nest, but
not smaller than the number of observations at the interim analysis (nest/2).
Table 3 shows estimated test sizes under the null of no treatment effect for some of
the simulated settings. In all cases the achieved test size is within simulation noise of the
target 2.5%, and there is no evidence of difference in size between the two procedures:
the mean values were 2.59% for fixed sample size and 2.58% for BSSR.
6.2 Power simulation of BSSR procedure vs. fixed sample size
estimation
In further simulations to assess the test power, we again assume nuisance parameters
λ = 2, a = 0.5 and η = 1 when calculating the fixed sample size, but generate data under
alternative true values. The procedure is as follows.
1. A sample size estimation is performed by plugging the assumed nuisance
parameters and θ∗ = 0.8 into the sample size formula (4). Using the assumed
nuisance parameters, the estimated sample size of the control and treatment group
are both given by nest = 165.
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Table 3. Comparison of type I error for α = 0.025 when using blinded sample size estimation
(bold font) and using only the fixed design (normal font).
λ
a η 1.5 1.9 2.1 2.5
0.30 0.50 2.46 2.38 2.52 2.53 2.71 2.78 2.64 2.77
0.70 2.45 2.51 2.63 2.82 2.70 2.68 2.82 2.59
0.90 2.71 2.38 2.54 2.37 2.65 2.87 2.68 2.53
1.10 2.67 2.64 2.57 2.50 2.57 2.67 2.70 2.83
1.30 2.63 2.44 2.57 2.30 2.42 2.31 2.46 2.39
1.50 2.56 2.58 2.44 2.60 2.59 2.53 2.87 2.72
0.40 0.50 2.73 2.49 2.83 2.60 2.60 2.38 2.56 2.64
0.70 2.76 2.92 2.76 2.79 2.25 2.44 2.59 2.70
0.90 2.46 2.45 2.58 2.62 2.46 2.37 2.59 2.55
1.10 2.66 2.65 2.55 2.55 2.80 2.62 2.64 2.58
1.30 2.54 2.54 2.68 2.53 2.67 2.71 2.48 2.60
1.50 2.51 2.52 2.60 2.67 2.72 2.75 2.60 2.64
0.50 0.50 2.41 2.34 2.66 2.50 2.44 2.27 2.59 2.78
0.70 2.68 2.78 2.43 2.78 2.71 2.58 2.57 2.74
0.90 2.39 2.49 2.73 2.71 2.57 2.48 2.55 2.47
1.10 2.39 2.53 2.37 2.54 2.77 2.74 2.42 2.40
1.30 2.65 2.60 2.68 2.54 2.57 2.68 2.53 2.45
1.50 2.60 2.69 2.49 2.47 2.71 2.53 2.69 2.79
0.60 0.50 2.65 2.42 2.46 2.70 2.51 2.48 2.37 2.67
0.70 2.43 2.63 2.63 2.57 2.57 2.89 2.66 2.99
0.90 2.64 2.59 2.73 2.44 2.58 2.54 2.71 2.96
1.10 2.57 2.62 2.61 2.82 2.75 2.90 2.60 2.67
1.30 2.34 2.33 2.79 2.55 2.66 2.56 2.28 2.19
1.50 2.57 2.68 2.55 2.49 2.68 2.73 2.69 2.47
0.70 0.50 2.59 2.75 2.43 2.65 2.50 2.65 2.58 2.86
0.70 2.70 2.69 2.76 2.61 2.43 2.94 2.28 2.77
0.90 2.54 2.45 2.65 2.34 2.56 2.53 2.60 2.87
1.10 3.08 2.81 2.51 2.54 2.37 2.39 2.72 2.71
1.30 2.48 2.44 2.67 2.54 2.43 2.42 2.76 2.66
1.50 2.82 2.72 2.80 2.80 2.35 2.49 2.57 2.56
2. Next nest/2 observations are simulated for the control and treatment group
respectively, corresponding to the first half of patients, and with a true treatment
effect of θ = 0.8 and various selections of nuisance parameters.
3. A blinded sample size reestimation is performed on these observations, upon
which the number of further simulated observations is increased according to the
reestimated sample size nreest.
4. Finally, the attained power of the fixed design based on the initial nest = 165
observations in each group is compared to the power of the BSSR design based
on nreest observations in each group. The number of observations in the BSSR
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design is allowed to be higher or smaller than nest, but not smaller than the number
of observations at the interim analysis, i.e. nest/2.
Figure 4 shows estimated power when the nuisance parameters are varied one at a time.
In all cases we see that a misspecification of the nuisance parameters will lead to over- or
underpowered studies when the sample size is not adjusted properly. The loss in power
can be dramatic, especially when the dependency or shape parameters are misspecified.
A proper sample size review however, will lead to an appropriate sample size which
maintains the desired power.
Figure 4. Left : The true overall rate is altered while keeping the true correlation parameter at
a = 0.5 and shape parameter η = 1. Center : The true correlation parameter is altered while
keeping the true overall lesion rate at λ = 2 and shape parameter η = 1. Right : The true
shape parameter is altered while keeping the true overall lesion rate at λ = 2 and the true
correlation parameter at a = 0.5.
6.3 Using observations with incomplete follow up
We now consider the effect of using observations from patients with incomplete follow
up, using the same basic simulation scenario as in the previous section, but with fixed
nuisance parameters λ = 2, a = 0.5 and η = 1. The recruitment scheme is assumed to
correspond to that in Figure 2, with 10 patients being recruited at each time point. In
contrast to performing the sample size review after a specified number of patients have
been fully observed, the sample size review is now performed at a specified time. Table
4 compares the sample size estimates when using BSSR with incomplete observations to
BSSR without incomplete observations as the review time is varied.
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Table 4. Mean and standard deviation of sample size estimates at different review time
points.
Incomplete Observations Complete Observations
Month of Review Mean SD Mean SD
8 164.9 15.9 164.4 23.6
10 165.1 13.1 165.0 16.5
12 165.3 11.5 165.2 13.7
14 165.2 10.4 165.1 11.8
16 165.3 9.4 165.3 10.5
The main benefit of including data from incomplete observations lies in a higher
precision for the estimated sample size. In this example, taking into account incomplete
observations enables a sample size review 2 months earlier, while maintaining the same
precision.
7 Discussion
The presented method allows for sample size calculation, blinded sample size
recalculation and inference within a reparametrised version of the NB-INAR(1) model.
Within this model, the presented sample size calculations are accurate and the inference
method maintains the nominal significance level. Adjustments to sample size within
a running trial did not show any inflation of the significance level and may thus be
considered in MS and other clinical trials with longitudinal count data. Especially in
situations where the sample size estimates are sensitive to nuisance parameters and good
estimates of nuisance parameters are difficult to attain for an initial sample size estimate,
the blinded sample size estimation can be of great benefit. From Section 4.1 we observed,
that misspecifications of the overall rate and shape parameter have a large influence when
these are near zero. Further, misspecifications of the correlation parameter influence
the sample size more when the number of time points is high and the correlation is
near 1, than in the case of independent observations and less time points. By further
incorporating incomplete observations, the precision of sample size reestimation can be
markedly improved.
Although the methods work well within the NB-INAR(1) model, there is space for
improvement outside of this model. For instance, a smoother estimation of the time
series could be obtained by considering an autoregressive process of higher order, NB-
INAR(p) with p > 1. For further details on how to generally extend the binomial thinning
model to higher orders, we refer to McKenzie17 and Alzaid.47 Furthermore, our approach
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does not allow for patient-specific covariates nor variation in lesion rates over time.
While individual covariate information would not be available at pre-trial sample size
estimation, considering covariates in inference has become popular among MS studies
and population characteristics might therefore also be considered in sample size planning.
Turning to time trends, in some trials it might be expected that the mean count changes
systematically with time. If this is because of an initial stabilization period as treatment
takes effect, then it may be sensible to use our model after a burn-in period to allow for
levelling-off of trends, discarding the early time points. More generally it is possible to
include time-variation in the model by allowing the parameters of the distribution of the
innovation W (t)ij in (1) to depend on time t. However, this way of incorporating a trend
results in marginal distributions that are no longer negative binomial. Another possibility
for introducing time variation while maintaining the property of marginal negative
binomial observations, is given by gamma frailty models.12,14 Here the conditional
distribution of counts at time t for individual j, given time-varying frailty Z(t)j , is
Poisson with mean Z(t)j µ
(t)
j for arbitrarily parametrised mean µ
(t)
j . The frailties are
constructed with marginal gamma distributions and between-time associations, leading
to the desired characteristics of negative binomial marginals and within-patient serial
correlation. Time trends and the effect of patient-specific covariates can be modelled
through µ(t)j . The model is limited, however, in the correlation structures that can be
described and, importantly, has no closed expression for the likelihood. Overcoming
these drawbacks and implementing sample size reestimation techniques within gamma
frailty models may be an appropriate subject for future research.
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Appendix
A Proof of marginal negative binomial distribution
Assumption: For reasons of readability, we omit group and patient specific indexing
within the following proof. We define following random variables:
• U (t) i.i.d.∼ Beta(aη, (1− a)η) for t = 2, ..., T
• B(t)k (p)
i.i.d.∼ Bernoulli(p) for t = 2, ..., T and k ∈ N
• X(1) ∼ NB(λ, η)
• W (t) i.i.d.∼ NB(aλ, aη) for t = 2, ..., T
• V (t) =
X(t−1)∑
k=0
B
(t)
k (U
(t)) for t = 2, ..., T
• X(t) = V (t) +W (t) for t = 2, ..., T
Claim: Then it holds, that X(t) ∼ NB(λ, η) for t = 1, ..., T .
Proof: For t = 1 the claim holds by definition. For t = 2 we first consider the
distribution of V (2). It holds that:
P
(
V (2) = y
)
= P
X(1)∑
k=1
B
(2)
k (U
(2)) = y

=
∞∑
n=0
P
(
X(1) = n
)
· P
(
n∑
k=1
B
(2)
k (U
(2)) = y
)
=
∞∑
n=0
P
(
X(1) = n
)
·
1∫
0
P
(
n∑
k=1
B
(2)
k (p) = y
)
· p
aη−1(1− p)(1−a)η−1
B(aη, (1− a)η) dp
=
∞∑
n=0
P
(
X(1) = n
)
·
1∫
0
(
n
y
)
py(1− p)n−y · p
aη−1(1− p)(1−a)η−1
B(aη, (1− a)η) dp
=
∞∑
n=0
P
(
X(1) = n
)(n
y
)
B(aη, (1− a)η)−1 ·
1∫
0
py+aη−1(1− p)n−y+(1−a)η−1dp
=
∞∑
n=0
P
(
X(1) = n
)(n
y
)
B(y + aη, n− y + (1− a)η)
B(aη, (1− a)η) dp
=
∞∑
n=0
(
η
η + λ
)η
Γ(n+ η)
Γ(n+ 1)Γ(η)
(
λ
η + λ
)n
·
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Γ(n+ 1)Γ(y + aη)Γ(n− y + (1− a)η)Γ(η)
Γ(y + 1)Γ(n− y + 1)Γ(n+ η)Γ(aη)Γ((1− a)η)
=
∞∑
n=0
(
η
η + λ
)η
Γ(y + aη)
Γ(y + 1)Γ(aη)
(
λ
η + λ
)n
Γ(n− y + (1− a)η)
Γ(n− y + 1)Γ((1− a)η)
=
(
η
η + λ
)η
Γ(y + aη)
Γ(y + 1)Γ(aη)
∞∑
m=0
(
λ
η + λ
)m+y
Γ(m+ (1− a)η)
Γ(m+ 1)Γ((1− a)η)
=
(
aη
aη + aλ
)aη
Γ(y + aη)
Γ(y + 1)Γ(aη)
(
aλ
aη + aλ
)y
·
∞∑
m=0
(
λ
η + λ
)m
Γ(m+ (1− a)η)
Γ(m+ 1)Γ((1− a)η)
(
(1− a)η
(1− a)η + (1− a)λ
)(1−a)η
︸ ︷︷ ︸
Is probability function ofNB((1−a)λ,(1−a)η) random variable
=
(
aη
aη + aλ
)aη
Γ(y + aη)
Γ(y + 1)Γ(aη)
(
aλ
aη + aλ
)y
⇒ V (2) ∼ NB(aλ, aη)
Calculating the characteristic function of X(2) shows:
ϕX(2)(u) = ϕV (2)(u) · ϕW (2)(u)
=
(
aη
(1− eiu)aλ+ aη
)aη
·
(
(1− a)η
(1− eiu)(1− a)λ+ (1− a)η
)(1−a)η
=
(
η
(1− eiu)λ+ η
)η
⇒ X(2) ∼ NB(λ, η)
For t = 3, ..., T the distribution of X(t) ∼ NB(λ, η) clearly follows by induction over t.
B Proof of covariance between time points
Assumption: For reasons of readability, we omit group and patient specific indexing
within the following proof. We define following random variables:
• U (t) i.i.d.∼ Beta(aη, (1− a)η) for t = 2, ..., T
• B(t)k (p)
i.i.d.∼ Bernoulli(p) for t = 2, ..., T and k ∈ N
• X(1) ∼ NB(λ, η)
• W (t) i.i.d.∼ NB(aλ, aη) for t = 2, ..., T
• V (t) =
X(t−1)∑
k=0
B
(t)
k (U
(t)) for t = 2, ..., T
• X(t) = V (t) +W (t) for t = 2, ..., T
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Claim: Then it holds, that Cov(Xt, Xt+s) = as · (λ2η + λ).
Proof:
Cov
(
X(t), X(t+s)
)
= E
(
X(t) ·X(t+s)
)
− E
(
X(t)
)
· E
(
X(t+s)
)
= E
(
E
(
X(t) ·X(t+s)|X(t+s−1)
))
− E
(
X(t)
)
· E
(
E
(
X(t+s)|X(t+s−1)
))
= E
E
X(t) · X(t+s−1)∑
k=1
B
(t+s)
k (U
(t+s)) +W (t+s)|X(t+s−1)

− E
(
X(t)
)
· E
E
X(t+s−1)∑
k=1
B
(t+s)
k (U
(t+s)) +W (t+s)|X(t+s−1)

= E
X(t) · E
X(t+s−1)∑
k=1
B
(t+s)
k (U
(t+s))|X(t+s−1)
−
E
(
X(t)
)
· E
E
X(t+s−1)∑
k=1
B
(t+s)
k (U
(t+s))|X(t+s−1)

+ E
(
X(t) ·W (t+s)
)
− E
(
X(t)
)
E
(
W (t+s)
)
= E
(
X(t) ·X(t+s−1) · E
(
B
(t+s)
k (U
(t+s))
))
−
E
(
X(t)
)
· E
(
X(t+s−1)E
(
B
(t+s)
k (U
(t))
))
+ E
(
X(t) ·W (t+s−1)
)
− E
(
X(t)
)
· E
(
W (t+s−1)
)
= E
(
B
(t+s)
k (U
(t))
)
·
(
E
(
X(t)X(t+s−1)
)
− E
(
X(t)
)
E
(
X(t+s−1)
))
= a · Cov
(
X(t), X(t+s−1)
)
⇒ Cov
(
X(t), X(t+s)
)
= as · Cov
(
X(t), X(t)
)
= as ·
(
λ2
η
+ λ
)
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